A series of 1-aryl-3-(3,5-dioxo-4-azatetracyclo[5.3.2.02,6.08,10]dodec-11-en-4-yl)urea derivatives were synthesized and studied for antiviral activity against smallpox vaccine virus. 3-(3,5-Dioxo-4-azatetracyclo-[5.3.2.02,6.08,10]dodec-11-en-4-yl)-1-(4-methylphenyl)urea, 3-(3,5-dioxo-4-azatetracyclo[5.3.2.02,6.08,10]dodec-11-en-4-yl)-1-(3-fluorophenyl)urea hydrate, and 3-(3,5-dioxo-4-azatetracyclo[5.3.2.02,6.08,10]dodec-11-en-4-yl)-1-(phenyl)thiourea showed pronounced activity.
Similar content being viewed by others
References
T. R. Bailey, S. R. Rippin, E. Opsitnick, et al., J. Med. Chem., 50(7), 1442 – 1444 (2007).
R. Jordan, T. R. Bailey, S. R. Rippin, and D. Dai, US Pat. Appl. No. 20120020922, Jan. 26, 2012; Chem. Abstr., 156, 222467 (2012).
B. A. Selivanov, A. Ya. Tikhonov, et al., RU Pat. No. 2,412,168, Feb. 20, 2011; Chem. Abstr., 154, s).
B. A. Selivanov, A. Ya. Tikhonov, et al., RU Pat. No. 2,440,983, Jan. 27, 2012; Chem. Abstr., 156, 230441 (2012).
B. A. Selivanov, A. Ya. Tikhonov, et al., RU Pat. No. 2,423,359, Jun. 10, 2011; Chem. Abstr., 155, 173303 (2011).
B. A. Selivanov, A. Ya. Tikhonov, et al., RU Pat. No. 2,424,800, Jul. 27, 2011; Chem. Abstr., 155, 231116 (2011).
B. A. Selivanov, A. Ya. Tikhonov, et al., RU Pat. No. 2,412,167, Feb. 20, 2011; Chem. Abstr., 154, 276034 (2011).
B. A. Selivanov, E. F. Belanov, N. I. Bormotov, et al., Dokl. Akad. Nauk, 441(3), 414 – 418 (2011).
T. K. Venkatachalam, C. Mao, and F. M. Uckun, Bioorg. Med. Chem., 12(15), 4275 – 4284 (2004).
M. Verma, K. N. Singh and E. D. Clercq, Heterocycles, 68(1), 11 – 22 (2006).
J. D. Bloom, R. G. Dushin, K. J. Curran, et al., Bioorg. Med. Chem. Lett., 14(13), 3401 – 3406 (2004).
P. P. Seth, R. Ranken, D. E. Robinson, et al., Bioorg. Med. Chem. Lett., 14(22), 5569 – 5572 (2004).
M. S. Mohamed, M. M. Kamel, E. M. M. Kassem, et al., Eur. J. Med. Chem., 45(10), 3311 – 3319 (2010).
M. A. Hassan, A. M. M. Younes, M. M. Taha, et al., Eur. J. Chem., 2(4), 514 – 518 (2011).
M. Struga, J. Kossakowski, E. Kedzierska, et al., Chem. Pharm. Bull., 55(5), 796 – 799 (2007).
J. Llompart, J. Galvez, and K. Pal, US Pat. Appl. No. 20060014770, Jan. 19, 2006; Chem. Abstr., 144, 121774 (2006).
K. Kojiri, H. Kondo, et al., US Pat. No. 5,591,842, Jan. 7, 1997; Chem. Abstr., 126, 157762 (1997).
P. Yogeeswari, D. Sriram, V. Saraswat, et al., Eur. J. Pharm. Sci., 20(3), 341 – 346 (2003).
M. J. Kornet, W. Beaven, and T. Varia, J. Heterocycl. Chem., 22(4), 1089 – 1091 (1985).
D. Atukuri, P. Kattimani, and R. Kamble, Org. Commun., 4(4), 94 – 104 (2011).
B. Stanovnik and M. Tisler, Org. Prep. Proced. Int., 5(2), 87 – 93 (1973).
A. N. Mironov, Handbook for Preclinical Drug Trials [in Russian], Part 1, Ministry of Public Health and Social Development of the RF, FGBU Scientific Centre for the Expert Evaluation of Medicinal Products, Moscow (2012).
Author information
Authors and Affiliations
Corresponding author
Additional information
E. F. Belanov is deceased
Translated from Khimiko-Farmatsevticheskii Zhurnal, Vol. 51, No. 6, pp. 13 – 17, June, 2017.
Rights and permissions
About this article
Cite this article
Selivanov, B.A., Tikhonov, A.Y., Belanov, E.F. et al. Synthesis and Antiviral Activity of 1-Aryl-3-(3,5-Dioxo-4-Azatetracyclo-[5.3.2.02,6.08,10]Dodec-11-EN-4-YL)Ureas. Pharm Chem J 51, 439–443 (2017). https://doi.org/10.1007/s11094-017-1629-9
Received:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s11094-017-1629-9